 |
Corporate News
06-Oct-23
|
|
|
|
|
|
|
|
|
|
|
|
Biocon partners with Juno Pharmaceuticals
|
|
To manufacture and supply Liraglutide in Canadian market
|
|
|
|
|
|
Biocon announced the signing of a partnership agreement with
Juno Pharmaceuticals, a specialty pharmaceutical company in Canada, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.
Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market.
|
|
|
|
Previous News |
Biocon Ltd soars 3.52%, Gains for third straight session
(
Hot Pursuit
-
11-Jun-25
13:05
)
|
|
|
Biocon gets CDSCO approval for Liraglutide drug substance
(
Hot Pursuit
-
03-Jun-25
08:23
)
|
|
|
Biocon Biologics announces extension of insulin supply agreement with Govt. of Malaysia
(
Corporate News
-
22-May-25
09:19
)
|
|
|
Biocon Ltd spurts 1.3%, up for five straight sessions
(
Hot Pursuit
-
19-May-25
13:00
)
|
|
|
Biocon's subsidiary get US FDA nod for anticoagulant medication Rivaroxaban
(
Hot Pursuit
-
16-May-25
09:38
)
|
|
|
Biocon
(
Results
-
Analysis
09-May-25
10:36
)
|
|
|
Biocon to hold AGM
(
Corporate News
-
09-May-25
09:23
)
|
|
|
Board of Biocon recommends final dividend
(
Corporate News
-
09-May-25
09:23
)
|
|
|
Biocon consolidated net profit rises 154.24% in the March 2025 quarter
(
Results
-
Announcements
09-May-25
07:38
)
|
|
|
Biocon edges higher after biologics arm secures multiple market access deals for Yesintek
(
Hot Pursuit
-
05-May-25
09:31
)
|
|
|
Biocon’s board OKs to raise Rs 4,500-cr
(
Hot Pursuit
-
24-Apr-25
08:11
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|